Share Twitter LinkedIn Facebook Email Celestia S. Higano, MD, shares her thoughts on how immunotherapy is currently being integrated into castrate resistant prostate cancer treatment algorithms.
Pioneering Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics for Tailored Treatment [39 SLIDES] Prostate 5 Mins Read
Promontory Therapeutics: PT-112 triggers organelle stress and ribosomal inhibition Prostate 2 Mins Read